Drugs, Pharmaceutical Companies, Structure Based Drug Design (SBDD) and Targeted Protein Degradation

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Drugs

Pharmaceutical Companies

Structure Based Drug Design (SBDD)

Targeted Protein Degradation

Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

The Pharma Data

DECEMBER 21, 2020

. Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe. Captor’s Optigradeä platform is focused on improving the selectivity and performance of first-generation degrader drugs. TOKYO and CAMBRIDGE, England , Dec.

Targeted Protein Degradation

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs

Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences

The Pharma Data

JANUARY 31, 2021

Ion channels represent a large but under-exploited class of drug targets beyond G protein-coupled proteins (GPCRs). Collaboration combines Sosei Heptares’ leading structure-based drug design platform with Metrion Biosciences’ ion channel expertise.

Structure Based Drug Design (SBDD)

Structure Based Drug Design (SBDD) Targeted Protein Degradation Drugs International

Drug Discovery Digest

Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences

Stay Connected